search
for
 About Bioline  All Journals  Testimonials  Membership  News  Donations


Memórias do Instituto Oswaldo Cruz
Fundação Oswaldo Cruz, Fiocruz
ISSN: 1678-8060
EISSN: 1678-8060
Vol. 105, No. 5, 2010, pp. 698-705
Bioline Code: oc10118
Full paper language: English
Document type: Research Article
Document available free of charge

Memórias do Instituto Oswaldo Cruz, Vol. 105, No. 5, 2010, pp. 698-705

 en Evaluation of local immune response to Fasciola hepatica check for this species in other resources experimental infection in the liver and hepatic lymph nodes of goats immunized with Sm14 vaccine antigen
Mendes, Ricardo E.; Zafra, Rafael; Pérez-Écija, Rafael A.; Buffoni, Leandro; Martínez-Moreno, Álvaro; Tendler, Miriam & Pérez, José

Abstract

Protection against Fasciola hepatica check for this species in other resources in goats immunized with a synthetic recombinant antigen from Schistosoma mansoni check for this species in other resources fatty acid-binding protein 14 (rSm14) was investigated by assessing worm burdens, serum levels of hepatic enzymes, faecal egg count and hepatic damage, which was evaluated using gross and microscopic morphometric observation. The nature of the local immune response was assessed by examining the distribution of CD2+, CD4+, CD8+ and γ´+ T lymphocytes along with IgG+, IL-4+ and IFN-γ+ cells in the liver and hepatic lymph nodes (HLN). The goats used consisted of group 1 (unimmunized and uninfected), group 2 [infected control - immunized with Quillaia A (Quil A)] and group 3 (immunized with rSm14 in Quil A and infected), each containing seven animals. Immunization with rSm14 in Quil A adjuvant induced a reduction in gross hepatic lesions of 56.6% (p < 0.001) and reduced hepatic and HLN infiltration of CD2+, CD4+, CD8+ and γ´+ T lymphocytes as well as IL-4+ and IFN-γ+ cells (p < 0.05). This is the first report of caprine immunization against F. hepatica using a complete rSm14 molecule derived from S. mansoni. Immunization reduced hepatic damage and local inflammatory infiltration into the liver and HLN. However, considering that Quil A is not the preferential/first choice adjuvant for Sm14 immunization, further studies will be undertaken using the monophosphoryl lipid A-based family of adjuvants during clinical trials to facilitate anti-Fasciola vaccine development.

Keywords
Sm14 - Fasciola hepatica - vaccines - goat - liver - parasite infection

 
© Copyright © 2010 - Instituto Oswaldo Cruz - Fiocruz
Alternative site location: http://memorias.ioc.fiocruz.br

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2017, Site last up-dated on 16-Oct-2017.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil